Cargando…

An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report

BACKGROUND: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor survival outcomes obtained with conventional scheduled chemotherapy. This case rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliato, Debora de Melo, Linck, Rudinei Diogo Marques, Bezerra, Regis Otaviano Franca, Souto, Mirela, Lopes, Gabriel Lima, Baiocchi, Glauco, Mano, Max Senna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790046/
https://www.ncbi.nlm.nih.gov/pubmed/26971567
http://dx.doi.org/10.1186/s13256-016-0837-3
_version_ 1782420940310708224
author Gagliato, Debora de Melo
Linck, Rudinei Diogo Marques
Bezerra, Regis Otaviano Franca
Souto, Mirela
Lopes, Gabriel Lima
Baiocchi, Glauco
Mano, Max Senna
author_facet Gagliato, Debora de Melo
Linck, Rudinei Diogo Marques
Bezerra, Regis Otaviano Franca
Souto, Mirela
Lopes, Gabriel Lima
Baiocchi, Glauco
Mano, Max Senna
author_sort Gagliato, Debora de Melo
collection PubMed
description BACKGROUND: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor survival outcomes obtained with conventional scheduled chemotherapy. This case report represents the first-ever reported objective response to a metronomic chemotherapy regimen and adds to the current literature. CASE PRESENTATION: We describe a case of a Caucasian woman diagnosed with metastatic carcinosarcoma that had already been treated with multiple lines of conventional chemotherapy, with progressive disease. This patient had a surprising clinical and imaging response when treated with oral metronomic cyclophosphamide. CONCLUSIONS: We reviewed the mechanism of action implicated in metronomic chemotherapy, and correlated it with the biology of disease in carcinosarcoma. This information may add to the current literature, providing important insights to future clinical trials in this patient population.
format Online
Article
Text
id pubmed-4790046
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47900462016-03-15 An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report Gagliato, Debora de Melo Linck, Rudinei Diogo Marques Bezerra, Regis Otaviano Franca Souto, Mirela Lopes, Gabriel Lima Baiocchi, Glauco Mano, Max Senna J Med Case Rep Case Report BACKGROUND: Uterine carcinosarcoma is well known for its aggressive behavior. There is little evidence regarding the gold standard combination chemotherapy in metastatic or locally advanced carcinosarcoma, due to poor survival outcomes obtained with conventional scheduled chemotherapy. This case report represents the first-ever reported objective response to a metronomic chemotherapy regimen and adds to the current literature. CASE PRESENTATION: We describe a case of a Caucasian woman diagnosed with metastatic carcinosarcoma that had already been treated with multiple lines of conventional chemotherapy, with progressive disease. This patient had a surprising clinical and imaging response when treated with oral metronomic cyclophosphamide. CONCLUSIONS: We reviewed the mechanism of action implicated in metronomic chemotherapy, and correlated it with the biology of disease in carcinosarcoma. This information may add to the current literature, providing important insights to future clinical trials in this patient population. BioMed Central 2016-03-14 /pmc/articles/PMC4790046/ /pubmed/26971567 http://dx.doi.org/10.1186/s13256-016-0837-3 Text en © Gagliato et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Gagliato, Debora de Melo
Linck, Rudinei Diogo Marques
Bezerra, Regis Otaviano Franca
Souto, Mirela
Lopes, Gabriel Lima
Baiocchi, Glauco
Mano, Max Senna
An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
title An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
title_full An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
title_fullStr An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
title_full_unstemmed An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
title_short An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
title_sort uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790046/
https://www.ncbi.nlm.nih.gov/pubmed/26971567
http://dx.doi.org/10.1186/s13256-016-0837-3
work_keys_str_mv AT gagliatodeborademelo anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT linckrudineidiogomarques anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT bezerraregisotavianofranca anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT soutomirela anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT lopesgabriellima anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT baiocchiglauco anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT manomaxsenna anuncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT gagliatodeborademelo uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT linckrudineidiogomarques uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT bezerraregisotavianofranca uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT soutomirela uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT lopesgabriellima uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT baiocchiglauco uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport
AT manomaxsenna uncommonresponsetometronomictherapyinaheavilypretreatedpatientwithmetastaticcarcinosarcomaacasereport